Background
• The economic burden of multiple sclerosis (MS) exceeds $6.8 billion annually in the US 1 -A significant portion of this burden arises from disability caused by gait and motor disturbances 2
• Gait dysfunction in MS is estimated to incur direct medical costs averaging nearly $21,000 per patient annually in the US 3 • Approximately 75% of patients with MS experience clinically significant walking impairment 4
• Dalfampridine extended release tablets (D-ER; known as prolonged-release fampridine in Europe and as fampridine modified or sustained release elsewhere), 10 mg twice daily, has demonstrated an increase in walking speed and is approved in the US to improve walking in patients with MS 5
• There is a lack of information on the utilization of D-ER in a real-world environment. This study provides new insights into the economic impact of D-ER in a population of patients with MS in the US
Objective
• The objective of the study was to estimate walking impairment-related healthcare resource utilization before and after D-ER initiation, compared to a cohort of similar patients who did not initiate D-ER 
Baseline Characteristics
• Patient demographic and clinical characteristics were evaluated during the 12-month baseline period. Comorbidity burden was assessed via the Quan-Charlson comorbidity index (QCI).
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Individual comorbid conditions and presence of symptoms commonly associated with MS were assessed based on ICD-9-CM codes • Disease-modifying therapies and other pharmacotherapies were identified based on Generic Product Identifier (GPI) codes and Current Procedural Technology (CPT)/ Healthcare Common Procedure Coding System codes ( Table 2) Outcome Assessments
• Walking impairment-related medical encounters were defined by medical claims in which a relevant code for gait/movement disorder or gait-associated events/encounters 719.7x, 781.0x, 781.3x ) was observed during the associated visit • Walking impairment-related healthcare resource utilization was evaluated during the 12-month follow-up period, stratified by treatment versus control -Healthcare resource utilization included: emergency room visits, inpatient hospitalization, physician office visits, and other outpatient visits (including physical therapy [PT] and occupational therapy [OT] ). PT and OT visits were identified based on CPT codes -Metrics included the percent of patients with ≥1 visit, the mean number of visits per patient, and the total number of visits across all patients -Differences over time in these utilization metrics (change scores, defined as follow-up minus baseline) were calculated within each cohort
Statistical Analysis
• Continuous variables were compared between the treatment and control cohorts using 2-sample t tests or Kruskal-Wallis tests for normal or non-normally distributed data. Categorical variables were compared using chi-square tests or Fisher exact tests, as appropriate
• A propensity score model was developed to control for potential differences that may confound the association between treatment and outcome. Using logistic regression to determine the likelihood of each patient initiating D-ER versus not initiating D-ER, a 1:1 treatment-to-control greedy match was conducted using each patient's propensity score • Balance across cohorts was assessed using statistical testing and standardized differences.
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Standardized differences of more than 10% may be considered to have potential clinical significance • Change scores were compared across cohorts using 2-sample t tests
Results

Baseline Demographics and Clinical Characteristics
• Two cohorts of patients with MS were identified; treatment (n = 938) and control (n = 1,200).
Propensity score matching yielded 479 pairs available for analysis (Figure 1) • After matching, treatment and control cohorts had similar baseline demographic and clinical characteristics; mean age was 52 years and 49 years in the treatment and control cohorts, respectively (Table 1) • Overall comorbidity burden as measured by the QCI was similar in both cohorts after matching ( Table 2) -Muscular weakness or spasticity was the most frequent MS symptom, followed by disturbances of skin sensation; other symptoms were present in <10% of patients
Healthcare Utilization
• Change scores were calculated as follow-up minus baseline values for walking impairmentrelated healthcare resource utilization (Table 3) for matched treatment and control cohorts: -Total number of hospitalizations increased by 8 and 31; change in the mean number of hospitalizations per patient was 0.02 and 0.06, respectively; P = 0.0089 -Total number of emergency room visits changed by -3 and 6; change in the mean number of visits per patient was -0.01 and 0.01, respectively; P = 0.029 -Total neurologist office visits changed by -52 and 354; change in the mean number of neurology visits/patient was -0.11 and 0.74, respectively; P < 0.0001 -Total number of PT or OT visits increased by 92 and 1,455; change in the mean number of PT or OT visits per patient was 0.19 and 3.04, respectively; P < 0.0001
Limitations
• Walking-associated disorders may have been undercoded or miscoded within claims, potentially resulting in the underestimation of walking impairment-related healthcare burden • Race, education, disease severity, or types of MS were not assessed in the claims data, and these may have affected the outcomes • The study sample was taken from one large US commercial health plan, and results may not be generalizable to patients enrolled in non-commercial plans or outside the US
Conclusions
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